STOCK TITAN

Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 12:30 p.m. PT / 3:30 p.m. ET. The company focuses on leveraging the biology of the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. Adaptive has three commercial products and a robust clinical pipeline aimed at personalized medicine.

Positive
  • None.
Negative
  • None.

SEATTLE, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Adaptive Biotechnologies’ management is scheduled to present on Wednesday, February 16th at 12:30 p.m. Pacific Time / 3:30 p.m. Eastern Time.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Laura Cooper
205-908-5603
media@adaptivebiotech.com


FAQ

When is Adaptive Biotechnologies presenting at the BTIG conference?

Adaptive Biotechnologies will present on February 16 at 12:30 p.m. PT / 3:30 p.m. ET.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into products for disease diagnosis and treatment.

What are the commercial goals of Adaptive Biotechnologies?

The company aims to develop and commercialize immune-driven clinical products tailored to individual patients.

Is the BTIG conference open to the public?

No, BTIG hosted events are intended for prospective and existing BTIG clients only.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

638.28M
143.90M
1.93%
93.98%
6.07%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SEATTLE